Kidney Cancer Association Applauds UK Drug Approval

      Change of Tack Shows Policy Shift and Saves Lives Evanston, IL, February 5, 2009 – The National Institute of Health and Clinical Excellence (NICE), the review body for the UK’s National Health Service, yesterday reversed an earlier decision and approved a drug for metastatic renal cell carcinoma. The decision marks an enormous victory for advanced-stage kidney cancer patients as well as the advocates who applied pressure on NICE to change their policy regarding lifesaving drugs for terminal patients.   “This decision demonstrates the power of a unified voice,” said William Bro, president of the Kidney Cancer Association. “Patient advocates won’t sit back and watch decisions be made about their loved ones lives based on cost, not science. This drug and the three others still being reviewed are proven to be effective and we are delighted that thousands of deserving patients in the U.K. finally have access to life-saving drugs.”   The drug, sunitinib (Sutent) is a novel, oral treatment that shows overall survival greater than two years in advanced kidney cancer patients. In September 2008, NICE advised against the use of Sutent and three other drugs (Avastin, Nexavar and Torisel). The decision reflects a change in policy guidelines that give greater consideration to the value that society places on end-of-life treatments.   “The risk you run with a single payer system s...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

Dongyan Hu, Yu Hu, Jisheng Li, Xiuwen WangJournal of Cancer Research and Therapeutics 2018 14(12):1223-1226 Brain metastasis is synchronous to the diagnosis of renal cell carcinoma (RCC). The prognosis of brain metastasis in RCC with the current treatment options is dismissal. Therefore, we present a case of an elderly female patient with RCC showing a partial response of brain metastasis after 18 months of 600 mg once daily sorafenib treatment who underwent right-sided nephrectomy. Further, withdrawal of sorafenib resulted in psychiatric changes along with increased metastasis lesions, which were recovered upon resuming ...
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsDOACs can be safely administered to patients with brain tumors. In patients with primary brain tumors (i.e. glioma), DOACs appear to be safer than LMWH and should be considered for this indication.Figure.DisclosuresZwicker: Incyte: Research Funding; Parexel: Consultancy; Quercegen: Research Funding; Daiichi: Honoraria.
Source: Blood - Category: Hematology Authors: Tags: 332. Antithrombotic Therapy: Poster II Source Type: research
ConclusionIn patients with malignant intracranial tumors, there is no difference in the risk of ICH or other bleeding events between those on therapeutic anticoagulation with a DOAC or LMWH.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Tags: 332. Antithrombotic Therapy: Poster II Source Type: research
mTOR inhibitors are frequently used in the treatment of metastatic renal cell cancer (mRCC). mTOR regulates cell growth, proliferation, angiogenesis, and survival, and additionally plays an important role in immune regulation. Since mTOR inhibitors were shown to benefit immunosuppressive regulatory T-cell (Treg) expansion, this might suppress antitumor immune responses. Metronomic cyclophosphamide (CTX) was shown to selectively deplete Tregs.11/14/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
AbstractBlockade of programmed cell death-1 (PD-1) has become one of the most promising immunotherapies for many human cancers. However, immune-related adverse events can be produced by anti-PD-1 therapy. Uveitis is a rare but potentially devastating side effect of anti-PD-1 therapy. Delay in diagnosis or improper treatment may eventually lead to irreversible blindness. Therefore, it is important for the oncologist and the ophthalmologist to recognize and manage this adverse event properly in patients receiving anti-PD-1 therapy in a timely manner. Here we present a grade 4 panuveitis with bilateral serous retinal detachme...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Odd-skipped related transcription factor 1 (OSR1) suppresses tongue squamous cell carcinoma migration and invasion through inhibiting NF-κB pathway. Eur J Pharmacol. 2018 Sep 19;: Authors: Chen W, Zou A, Zhang H, Fu X, Yao F, Yang A Abstract Tongue squamous cell carcinoma (TSCC) is the most common cancers of oral, owing to the high invasive and metastatic ability, patients with TSCC have poor prognosis, it's important to explore the regulatory mechanism of TSCC invasion and metastasis. Previous studies suggest OSR1 suppresses the progression of gastric cancer and renal cell carcinoma, but its ro...
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharmacol Source Type: research
Androgens have been suspected to be involved in the initiation of renal cell carcinoma because of a two-fold increased risk in men compared with women. To investigate the role of self-reported finasteride or oral contraceptive use in the Prostate, Lung, Colorectal, and Ovarian (PCLO) to determine whether the androgen receptor reduces renal cancer development. We query the PCLO trial for predictor variables from the baseline questionnaire and follow-up questionnaires enquiring medication use, specifically the use of 5-α reductase inhibitors (dutasteride or finasteride) and oral contraceptive therapy. The primary outco...
Source: European Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Research Papers: Urologic Cancer Source Type: research
Conclusion.Concomitant PPI or H2RA usage was not shown to be associated with a reduction in PFS or OS for patients receiving pazopanib for mRCC, with a similar toxicity profile in each group. Based on the results of this retrospective cohort study and the palliative nature of the treatment of patients with mRCC, clinicians should consider allowing patients to remain on concomitant pazopanib and acid‐reducing therapy.Implications for Practice.Pazopanib is a preferred category‐one first‐line treatment for predominant clear cell metastatic renal cell carcinoma (mRCC). However, because of an aging demographic, coupled wi...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Genitourinary Cancer Source Type: research
miR‑30a‑5p inhibits the proliferation, migration and invasion of melanoma cells by targeting SOX4. Mol Med Rep. 2018 Jun 14;: Authors: Liu E, Sun X, Li J, Zhang C Abstract MicroRNA (miR)‑30a‑5p has been reported to suppress the progression of hepatocellular cancer, renal cell carcinoma, oral cancer and gastric cancer. However, whether miR‑30a‑5p is involved in the regulation of melanoma remains unclear. The present study revealed that miR‑30a‑5p was downregulated in melanoma tissues and cell lines. Overexpression of miR‑30a‑5p significantly inhibited the proliferation, migration and...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Contributors : Naohiko Seki ; Takayuki AraiSeries Type : Expression profiling by arrayOrganism : Homo sapiensTo identify differentially expressed genes by anti cancer treatments (microRNAs or siRNAs) in human cancer, several cell lines ( pancreatic cancer, renal cell carcinoma, oral squamous cell carcinoma, prostate cancer and bladder cancer) were subjected to Agilent whole genome microarrays.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Health | Kidney Cancer | Lessons | National Health Service (NHS) | National Institute for Health and Clinical Excelle | National Institutes of Health (NIH) | Oral Cancer | Renal Cell Carcinoma | Science | UK Health | Urology & Nephrology